Xencor Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Xencor Inc Unternehmen

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Xencor Inc Informationen



BörsenkürzelXNCR

Name des UnternehmensXencor Inc

IPO-datumDec 03, 2013

CEODahiyat (Bassil I)

Anzahl der mitarbeiter250

WertpapierartOrdinary Share

GeschäftsjahresendeDec 03

Addresse465 N. Halstead St.

StadtPASADENA

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl91107

Telefon16263055900

Websitehttps://xencor.com/

BörsenkürzelXNCR

IPO-datumDec 03, 2013

CEODahiyat (Bassil I)

Führungskräfte von Xencor Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

Dr. Bassil I. Dahiyat, Ph.D.

President, Chief Executive Officer, Founder and Director

--

Dr. A. Bruce Montgomery, M.D.

Lead Independent Director

--

Dr. Kevin C. Gorman, Ph.D.

Independent Director

--

Dr. Ellen Gwen Feigal, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31

Aktionäre

Aktionärstypen

Aktionäre

Anteil

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

Andere

42.90%

Aktionäre

Anteil

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

Andere

42.90%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

56.73%

Investment Advisor/Hedge Fund

36.40%

Hedge Fund

18.64%

Research Firm

3.84%

Individual Investor

1.34%

Venture Capital

1.05%

Pension Fund

0.91%

Bank and Trust

0.36%

Sovereign Wealth Fund

0.08%

Institutionelle Beteiligung



Aktualisiert: Wed, Jan 21

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q4

364

84.79M

119.03%

--

2025Q4

446

84.32M

118.08%

-5.51M

2025Q3

434

80.43M

112.65%

-6.04M

2025Q2

437

81.68M

114.52%

-1.81M

2025Q1

459

80.70M

113.40%

-3.00M

2024Q4

454

76.54M

108.64%

-2.55M

2024Q3

455

73.66M

105.55%

+3.66M

2024Q2

436

65.64M

106.20%

-4.06M

2024Q1

431

66.91M

108.52%

-498.74K

2023Q4

420

65.39M

107.20%

-1.62M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

PRIMECAP Management Company

10.68M

14.95%

+147.70K

+1.40%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.58M

14.82%

-92.56K

-0.87%

Sep 30, 2025

The Vanguard Group, Inc.

7.17M

10.04%

+80.65K

+1.14%

Nov 28, 2025

RTW Investments L.P.

6.22M

8.71%

+3.82M

+158.90%

Sep 30, 2025

EcoR1 Capital, LLC

6.14M

8.6%

--

Sep 30, 2025

BVF Partners L.P.

4.62M

6.47%

+1.88M

+68.58%

Oct 17, 2025

State Street Investment Management (US)

3.67M

5.14%

-143.78K

-3.77%

Sep 30, 2025

TCG Crossover Management, LLC

2.45M

3.43%

--

Sep 30, 2025

Geode Capital Management, L.L.C.

1.73M

2.42%

+25.16K

+1.48%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

1.59M

2.23%

-191.61K

-10.76%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Genomics Immunology and Healthcare ETF

2.09%

Tema Oncology ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

1.06%

Invesco NASDAQ Future Gen 200 ETF

0.97%

Invesco S&P SmallCap Health Care ETF

0.64%

ALPS Medical Breakthroughs ETF

0.43%

State Street SPDR S&P Biotech ETF

0.33%

Inspire Small/Mid Cap ESG ETF

0.3%

Direxion Daily S&P Biotech Bull 3X Shares

0.15%

ProShares Ultra Nasdaq Biotechnology

0.15%

iShares Genomics Immunology and Healthcare ETF

Anteil2.09%

Tema Oncology ETF

Anteil1.16%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.06%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.97%

Invesco S&P SmallCap Health Care ETF

Anteil0.64%

ALPS Medical Breakthroughs ETF

Anteil0.43%

State Street SPDR S&P Biotech ETF

Anteil0.33%

Inspire Small/Mid Cap ESG ETF

Anteil0.3%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.15%

ProShares Ultra Nasdaq Biotechnology

Anteil0.15%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten